Accelerating Access to Critical Therapies for ALS Reauthorization...
To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
HB8205, known as the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, aims to extend the provisions of the existing Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. This law helps ensure that patients with Amyotrophic Lateral Sclerosis (ALS), a terminal neurological disorder, can access critical therapies more quickly.
The bill would primarily affect individuals with ALS and their families, as well as healthcare providers and pharmaceutical companies involved in developing and distributing ALS treatments. By reauthorizing the current act, the bill intends to maintain and enhance the mechanisms that speed up the approval and delivery of therapies for ALS.
As of July 22, 2026, the bill has been passed in the House and is awaiting further action in the Senate. Recent actions include debate in the House, a motion to suspend the rules and pass the bill, and a vote to reconsider which was tabled without objection. The bill was reported by the Committee on Energy and Commerce on May 21, 2026, and underwent committee consideration and mark-up sessions.
